NXG — NexgenRx Cashflow Statement
0.000.00%
Last trade - 00:00- CA$15.60m
- CA$15.84m
- CA$13.85m
- 66
- 65
- 23
- 50
Annual cashflow statement for NexgenRx, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.208 | 2.12 | 4.02 | -0.022 | -0.332 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.237 | 0.187 | 0.069 | 0.089 | 0.062 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.266 | -0.287 | 0.425 | -0.582 | 0.229 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1.05 | 2.65 | 3.82 | 1.07 | 1.28 |
| Capital Expenditures | -0.051 | -0.121 | -0.127 | -0.389 | -0.077 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.906 | -0.957 | -1.24 | -0.118 | -0.171 |
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.957 | -1.08 | -1.37 | -0.507 | -0.248 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.395 | -1.3 | -0.94 | -1.11 | -0.919 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.307 | 0.275 | 1.52 | -0.55 | 0.11 |